FDA Clinical Hold for Histogen Trial in Knee Regeneration

Histogen was verbally notified about additional questions from FDA for the company’s Investigational New Drug (IND) application package for the planned Phase I/II clinical trial of HST-003. The trial is evaluating the human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and a knee cartilage defect to regenerate...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0